全球肝病负担:2026年更新
酒精性肝病、代谢功能障碍相关脂肪性肝病及慢性病毒性肝炎是主要病因,非洲肝硬化与肝癌年龄标化死亡率最高。
要点
- 主要病因为酒精性肝病、MASLD及慢性乙肝/丙肝。
- 非洲肝硬化与肝癌年龄标化死亡率最高,病毒性肝炎为主因。
核心结论
- 全球肝病负担持续加重,区域差异扩大,需整合预防、早期发现与公平可及的循证肝病照护。
研究设计与样本
- 综述,更新全球肝病负担评估,未报告系统检索方法与样本量。
主要发现
- 酒精性肝病、MASLD与慢性病毒性肝炎是主要病因。
- 非洲肝硬化与肝癌年龄标化死亡率最高,主要驱动因素为病毒性肝炎、黄曲霉毒素暴露与照护可及性受限。
- 急性肝衰竭虽罕见,但临床与经济后果显著,病因与结局存在明显区域差异。
临床怎么用
- 关注酒精性肝病与MASLD负担上升趋势,重视代谢疾病与酒精使用的交互作用。
- 肝硬化患者需监测失代偿、慢加急性肝衰竭与肝细胞癌风险。
- 病毒性肝炎的疫苗接种与抗病毒治疗可及性改善正在重塑其流行病学。
局限性
- 为综述性全球评估,未报告系统检索策略与原始数据来源细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic liver disease remains a major global health challenge, affecting more than 1.5 billion people worldwide and contributing to morbidity, mortality, and health care costs. Cirrhosis is the 12th leading cause of death globally and, together with primary liver cancer, accounts for nearly 2.4 million deaths annually-disproportionately affecting low- and middle-income countries. The principal etiologies driving the burden of liver disease include alcohol-associated liver disease, metabolic dysfunction-associated steatotic liver disease, and chronic viral hepatitis (ie, hepatitis B virus and hepatitis C virus). Demographic changes, rising obesity, and increasing alcohol consumption are expected to escalate the burden of alcohol-associated liver disease and metabolic dysfunction-associated steatotic liver disease, while improved access to vaccination and antiviral therapy continues to reshape the epidemiology of viral hepatitis. Acute liver failure, although rare, results in significant clinical and economic consequences and highlights striking regional disparities in etiology and outcomes. Cirrhosis carries an elevated risk of progression to hepatic decompensation, acute-on-chronic liver failure, and hepatocellular carcinoma. These complications are associated with limited access to advanced therapies in resource-restricted regions. Importantly, Africa now bears the highest age-standardized mortality rates from cirrhosis and liver cancer, driven largely by viral hepatitis, aflatoxin exposure, and constrained access to care. Liver transplantation remains lifesaving, but is accessible to a minority of patients globally. The escalating burden of metabolic dysfunction-associated steatotic liver disease, the growing interplay of metabolic disease and alcohol use, and persistent gaps in viral hepatitis diagnosis and treatment underscore the urgent need for integrated prevention, early detection, and equitable access to evidence-based liver care. This review provides an updated global assessment of the burden of liver disease, highlighting widening regional disparities, and outlining priorities and strategies for reducing its worldwide impact.
引用
- Devarbhavi H, Asrani SK, Arab JP, et al. Global Burden of Liver Disease: 2026 Update. Gastroenterology. 2026. PMID: 42790604. doi:10.1053/j.gastro.2026.09.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。